AcuCort AB (publ) (Spotlight Stock Market: ACUC), a Sweden-based biotechnology company, announced on Wednesday that it has signed an exclusive commercial agreement with Kamada Ltd., (NASDAQ: KMDA; TASE: KMDA.TA), an Israel-based global biopharmaceutical company.

The contract grants Kamada exclusive Israeli market rights to the marketing, sales and distribution of AcuCort's drug Zeqmelit for, among other things, treatment of acute allergy.

According to the terms of the contract, Kamada will be responsible for commercialisation of Zeqmelit in Israel and will have the exclusive right to marketing, sales, and distribution of the drug in this market. It is mandatory on Kamada to register Zeqmelit in Israel. Kamada's evaluation is that it will be able to implement for registration and market approval to the Israeli authority MOH, Ministry of Health, during the first quarter of 2023. The processing of the submitted application is likely to take place between 8 to 24 months.